Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress

LONDON and NEW HAVEN, Conn., Dec. 11, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) announced today that it presented clinical safety and efficacy data for BHV-1510 at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress, taking place from December 10-12, 2025, in London, United Kingdom. The presentation highlights Biohaven's novel next-generation trophoblast cell surface antigen 2 (Trop2) directed antibody drug conjugate (ADC), BHV-1510, in combination with Regeneron's anti-PD-1 cemiplimab demonstrating efficacy and manageable safety across several tumors.